Truist Financial Corp Decreases Stock Holdings in Bristol Myers Squibb Company $BMY

Truist Financial Corp reduced its position in Bristol Myers Squibb Company (NYSE:BMY) by 6.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,202,157 shares of the biopharmaceutical company’s stock after selling 89,305 shares during the period. Truist Financial Corp’s holdings in Bristol Myers Squibb were worth $64,844,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb in the 2nd quarter valued at approximately $25,000. Physician Wealth Advisors Inc. boosted its position in shares of Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares in the last quarter. EQ Wealth Advisors LLC purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter worth about $32,000. KERR FINANCIAL PLANNING Corp purchased a new stake in shares of Bristol Myers Squibb in the 3rd quarter worth about $35,000. Finally, JPL Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb in the 3rd quarter worth about $36,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Down 1.5%

Shares of NYSE:BMY opened at $57.36 on Tuesday. The company has a market capitalization of $117.11 billion, a P/E ratio of 16.11, a P/E/G ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The stock’s fifty day simple moving average is $59.56 and its 200-day simple moving average is $54.63.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The business had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.29 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.05% of the stock is owned by company insiders.

Analysts Set New Price Targets

BMY has been the topic of several recent research reports. Morgan Stanley reiterated an “underweight” rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Wells Fargo & Company reissued an “outperform” rating and set a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Scotiabank reissued a “sector perform” rating and set a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Royal Bank Of Canada initiated coverage on shares of Bristol Myers Squibb in a research note on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price objective for the company. Finally, UBS Group reissued a “buy” rating and set a $70.00 price objective on shares of Bristol Myers Squibb in a research note on Friday, March 6th. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $61.31.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.